DDInter1897 DDInter122
Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocorticoid receptor, however compared to mifepristone (a progesterone receptor antagonist), ulipristal is more tolerable and has lower glucocorticoid activity and better binding affinity. Ulipristal is currently recommended as first line therapy for emergency contraception, due to improved efficacy and similar side effect profile as compared to the traditional use of levonorgestrel or the Yuzpe regimen. The exact mechanism of action for ulipristal is still currently debated, though there is evidence that it functions by inhibiting ovulation. A recent systematic review proclaimed that the majority of available evidence demonstrates
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. Artesunate was granted FDA approval on 26 May 2020.
Ulipristal {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Ulipristal {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fluconazole
Ulipristal {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rivaroxaban
Ulipristal {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Ulipristal {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Ulipristal may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Ulipristal may cause a minor interaction that can limit clinical effects when taken with Fluconazole
Ulipristal may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Ulipristal may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Ulipristal may lead to a major life threatening interaction when taken with Edoxaban